RS50291B - Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem - Google Patents

Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem

Info

Publication number
RS50291B
RS50291B YUP-622/02A YUP62202A RS50291B RS 50291 B RS50291 B RS 50291B YU P62202 A YUP62202 A YU P62202A RS 50291 B RS50291 B RS 50291B
Authority
RS
Serbia
Prior art keywords
molsidomine
hours
released
oral administration
prolonged release
Prior art date
Application number
YUP-622/02A
Other languages
English (en)
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Limited, filed Critical Therabel Pharmaceuticals Limited,
Publication of YU62202A publication Critical patent/YU62202A/sh
Publication of RS50291B publication Critical patent/RS50291B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Čvrsti oralni galenski oblik molsidomina sa produženim oslobađanjem, naznačen time što sadrži terapeutski efikasnu količinu molsidomina ili jedan od njegovih aktivnih metabolita, odabranih od jedinjenja SIN-1 i SIN-1A i što ima in vitro brzinu rastvaranja [merenu spektrofotometrijski na 286 ili 311 nm prema metodi koja je opisana u Pharmacopee Europeenne, 3-će izdanje (ili U.S.P.XXIV) na 50 rpm (obrtaja/min) u 500ml u 0,1 N HC1, na 37°C] od : -15 do 25 % molsidomina oslobođenog nakon 1 sat - 20 do 35 % molsidomina oslobođenog posle 2 sata - 50 do 65 % molsidomina oslobođenog posle 6 sati - 75 do 95 % molsidomina oslobođenog posle 12 sati - > 85 % molsidomina oslobođenog posle 18 sati - > 90 % molsidomina oslobođenog posle 24 sata gde se pik molsidomina u plazmi postignut in vivo javlja za 2,5 do 5 sati, najčešće za 3 do 4 sata, posle administracije naznačenog oblika , i ima vrednosti između 25 i 40 ng/ml plazme. Prijava sadrži 11 zavisnih zahteva
YUP-622/02A 2000-02-24 2001-02-22 Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem RS50291B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0002307A FR2805462B1 (fr) 2000-02-24 2000-02-24 Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Publications (2)

Publication Number Publication Date
YU62202A YU62202A (sh) 2006-01-16
RS50291B true RS50291B (sr) 2009-09-08

Family

ID=8847342

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-622/02A RS50291B (sr) 2000-02-24 2001-02-22 Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem

Country Status (36)

Country Link
US (1) US7767227B2 (sr)
EP (1) EP1265614B1 (sr)
JP (1) JP4945043B2 (sr)
KR (1) KR100814191B1 (sr)
CN (1) CN100396284C (sr)
AT (1) ATE296632T1 (sr)
AU (2) AU2001240653B9 (sr)
BE (1) BE1013487A3 (sr)
BG (1) BG66111B1 (sr)
BR (1) BRPI0108041B8 (sr)
CA (1) CA2400886C (sr)
CZ (1) CZ301993B6 (sr)
DE (1) DE60111196T2 (sr)
DZ (1) DZ3273A1 (sr)
EE (1) EE05098B1 (sr)
ES (1) ES2241803T3 (sr)
FR (1) FR2805462B1 (sr)
HK (1) HK1050138B (sr)
HR (1) HRP20020692B1 (sr)
HU (1) HU229799B1 (sr)
IL (2) IL151205A0 (sr)
IS (1) IS2446B (sr)
MA (1) MA25576A1 (sr)
MD (1) MD3119C2 (sr)
MX (1) MXPA02008262A (sr)
NO (1) NO329495B1 (sr)
NZ (1) NZ520691A (sr)
OA (1) OA12183A (sr)
PL (1) PL201631B1 (sr)
PT (1) PT1265614E (sr)
RS (1) RS50291B (sr)
RU (1) RU2263506C2 (sr)
SK (1) SK286313B6 (sr)
UA (1) UA73972C2 (sr)
WO (1) WO2001062256A1 (sr)
ZA (1) ZA200206042B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2868314B1 (fr) * 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
EP2468269A1 (en) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation
BE1028879B1 (fr) 2020-12-11 2022-07-12 Europharmaceuticals Comprimé à libération prolongée de la molsidomine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen
CN1006522B (zh) * 1986-04-30 1990-01-24 田道制药有限公司 缓放性制剂的制备方法
HU212730B (en) * 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ATE185273T1 (de) * 1993-05-11 1999-10-15 Hoechst Ag Galenische zubereitungen von molsidomin
US5804214A (en) * 1993-07-08 1998-09-08 Cygnus, Inc. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
HU218280B (en) * 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
DE4443105C2 (de) * 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
JPH09114680A (ja) * 1995-10-19 1997-05-02 Fuji Xerox Co Ltd シーケンス制御装置
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
DE69828635T2 (de) * 1997-09-19 2005-06-16 Shire Laboratories, Inc. Feste lösungskügelchen
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Also Published As

Publication number Publication date
EP1265614B1 (fr) 2005-06-01
EE200200472A (et) 2003-12-15
ZA200206042B (en) 2003-07-29
MA25576A1 (fr) 2002-10-01
PT1265614E (pt) 2005-10-31
CZ301993B6 (cs) 2010-09-01
HRP20020692B1 (en) 2011-10-31
BRPI0108041B8 (pt) 2021-05-25
SK12202002A3 (sk) 2002-12-03
NZ520691A (en) 2004-07-30
JP2003523981A (ja) 2003-08-12
NO20024043L (no) 2002-08-23
NO20024043D0 (no) 2002-08-23
HUP0300607A2 (hu) 2003-08-28
BR0108041B1 (pt) 2013-06-18
PL357550A1 (en) 2004-07-26
IS2446B (is) 2008-11-15
HRP20020692A2 (en) 2004-02-29
CN100396284C (zh) 2008-06-25
IL151205A0 (en) 2003-04-10
DZ3273A1 (fr) 2001-08-30
HU229799B1 (en) 2014-07-28
AU2001240653B2 (en) 2005-05-26
IL151205A (en) 2011-01-31
DE60111196D1 (de) 2005-07-07
ES2241803T3 (es) 2005-11-01
MD3119C2 (ro) 2007-04-30
US20030045522A1 (en) 2003-03-06
YU62202A (sh) 2006-01-16
FR2805462A1 (fr) 2001-08-31
FR2805462B1 (fr) 2003-08-15
MD20020212A (en) 2002-12-31
CA2400886C (fr) 2011-04-19
PL201631B1 (pl) 2009-04-30
NO329495B1 (no) 2010-11-01
KR20020081323A (ko) 2002-10-26
DE60111196T2 (de) 2006-05-11
EP1265614A1 (fr) 2002-12-18
BG66111B1 (bg) 2011-05-31
CN1419451A (zh) 2003-05-21
BG107027A (bg) 2003-04-30
RU2263506C2 (ru) 2005-11-10
IS6504A (is) 2002-08-14
WO2001062256A1 (fr) 2001-08-30
KR100814191B1 (ko) 2008-03-17
HUP0300607A3 (en) 2006-02-28
OA12183A (fr) 2006-05-09
AU4065301A (en) 2001-09-03
HK1050138A1 (en) 2003-06-13
UA73972C2 (en) 2005-10-17
ATE296632T1 (de) 2005-06-15
SK286313B6 (en) 2008-07-07
BR0108041A (pt) 2002-10-29
JP4945043B2 (ja) 2012-06-06
MXPA02008262A (es) 2004-04-05
MD3119B2 (en) 2006-08-31
AU2001240653B9 (en) 2005-10-27
BE1013487A3 (fr) 2002-02-05
CA2400886A1 (fr) 2001-08-30
RU2002121503A (ru) 2004-03-20
HK1050138B (zh) 2005-07-29
EE05098B1 (et) 2008-12-15
US7767227B2 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
NO20043913L (no) Blandinger med modifisert frigjoring av i det minste en form av tramadol
ME00429B (me) Upotreba inhibitora sistema renin-angiotenzin za prevenciju kardiovaskularnih slučajeva
CA2346001A1 (en) Controlled release nanoparticulate compositions
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
BR9914251A (pt) Formulações orais de liberação sustentada
HUP0101512A2 (hu) Adhéziós mikrogyöngy hatóanyag-adagoló készítmény, eljárás az előállítására és a készítményt tartalmazó eszköz
SG145690A1 (en) Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
RS50291B (sr) Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem
WO2006123360A3 (en) Microspheres containing octreotide acetate
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
AU2003232535A1 (en) "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
RS54791B1 (sr) Oralni sastav molsidomina sa produženim oslobađanjem za aterosklerozu
ECSP993104A (es) Nueva formulacion oral
CR6300A (es) Nueva formulacion oral